{"id":"triptorelin-gnrh-agonists","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"40-60","effect":"Erectile dysfunction"},{"rate":"40-50","effect":"Decreased libido"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Gynecomastia"},{"rate":null,"effect":"Bone density loss (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL1200554","moleculeType":"Protein","molecularWeight":"1699.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triptorelin binds to GnRH receptors on pituitary gonadotroph cells, triggering an initial surge in LH and FSH release. With continuous exposure, the pituitary becomes desensitized and downregulates GnRH receptors, resulting in profound suppression of testosterone and estrogen production. This sustained hormonal suppression is therapeutically exploited in hormone-dependent cancers and certain reproductive disorders.","oneSentence":"Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing sustained suppression through receptor desensitization.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:37.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Breast cancer (premenopausal women)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Central precocious puberty"}]},"trialDetails":[{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT06691815","phase":"NA","title":"Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital de Niños R. Gutierrez de Buenos Aires","startDate":"2022-08-01","conditions":"Pubertal Delay, Hypogonadism, Hypogonadotropic, Constitutional Delay in Growth and Puberty (CDGP)","enrollment":48},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT04854707","phase":"","title":"An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2020-01-12","conditions":"Reproductive Issues, Reproductive Disorder, Fertility Disorders","enrollment":5484},{"nctId":"NCT03717870","phase":"NA","title":"Surgery and ART For Endometrioma","status":"NOT_YET_RECRUITING","sponsor":"Università degli Studi dell'Insubria","startDate":"2023-10","conditions":"Ovarian Endometrioma, Infertility, Female","enrollment":100},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":"Prostate Cancer","enrollment":397},{"nctId":"NCT02737800","phase":"NA","title":"Effect of Prolonged GnRh Agonists on Results of Intracytoplasmic Sperm Injection (ICSI ) in Endometrioma Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2016-04","conditions":"Endometrioma","enrollment":88},{"nctId":"NCT03307720","phase":"NA","title":"Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)","status":"UNKNOWN","sponsor":"Ginegorama S.L.","startDate":"2017-12-18","conditions":"Ovulation Induction, In Vitro Fertilization (IVF), Infertility, Female","enrollment":300},{"nctId":"NCT03353883","phase":"PHASE2, PHASE3","title":"Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?","status":"UNKNOWN","sponsor":"Benha University","startDate":"2017-06-01","conditions":"Infertility, Female","enrollment":200},{"nctId":"NCT01638026","phase":"PHASE4","title":"Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-09","conditions":"Infertility","enrollment":93},{"nctId":"NCT03071172","phase":"PHASE3","title":"Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-03","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":252},{"nctId":"NCT01590173","phase":"PHASE2, PHASE3","title":"Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2012-01","conditions":"Infertility","enrollment":86},{"nctId":"NCT01798862","phase":"PHASE2, PHASE3","title":"Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2013-03","conditions":"Repeated Implantation Failures","enrollment":100},{"nctId":"NCT01603420","phase":"PHASE2, PHASE3","title":"External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer","status":"TERMINATED","sponsor":"Proton Collaborative Group","startDate":"2012-07","conditions":"Prostate Cancer","enrollment":2},{"nctId":"NCT00438217","phase":"PHASE4","title":"Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"","conditions":"Central Precocious Puberty","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Triptorelin (GnRH agonists)","genericName":"Triptorelin (GnRH agonists)","companyName":"University of Pisa","companyId":"university-of-pisa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing sustained suppression through receptor desensitization. Used for Advanced prostate cancer, Breast cancer (premenopausal women), Endometriosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}